Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease

Regine Kluge, Tim Wittig, Thomas W Georgi, Lars Kurch, Osama Sabri, W Hamish Wallace, Tomasz Klekawka, Ana Fernández-Teijeiro, Francesco Ceppi, Jonas Karlén, Jane Pears, Michaela Cepelová, Alexander Fosså, Auke Beishuizen, Lisa Lyngsie Hjalgrim, Dieter Körholz, Christine Mauz-Körholz, Dirk Hasenclever

8 Citationer (Scopus)

Abstract

In first-line treatment of Hodgkin lymphoma (HL), Deauville scores 1-3 define complete metabolic remission. Interim 18F-FDG PET is also used for relapse-treatment adaptation; however, PET response criteria are not validated for relapse treatment. Methods: We performed a pairwise comparative analysis of early response to first- and second-line treatments in 127 patients with classic HL who experienced relapse. The patients participated in the prospective, multicenter EuroNet-PHL-C1 study. Residual uptake was measured retrospectively using the qPET method, a validated semiautomatic quantitative extension of the Deauville score. Empiric cumulative distribution functions of the qPET values were used to systematically analyze the response to first- and second-line treatments. Results: Individual patients responded variably to first- and second-line treatments. However, the empiric cumulative distribution functions of the qPET values from all patients were nearly superimposable. Conclusion: The findings support that first- and second-line treatments in HL do not require different response criteria.

OriginalsprogEngelsk
TidsskriftJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Vol/bind62
Udgave nummer3
Sider (fra-til)338-341
Antal sider4
ISSN0161-5505
DOI
StatusUdgivet - mar. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease'. Sammen danner de et unikt fingeraftryk.

Citationsformater